EU Legal Opinion In Roche/Novartis Case Has Competition And Licensing Implications
A recent opinion from an EU advocate general is another blow for Roche and Novartis in their fight against an Italian fine imposed on them as a result of their agreement on the use of Avastin and Lucentis in wet AMD. If the opinion is followed by the court, it could have competition law consequences in areas such as product licensing.
You may also be interested in...
Another Knockback For Roche And Novartis As CJEU Rules On Italian Competition Case
In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.
Roche and Novartis continue fight against Italian fine despite court setback
Roche and Novartis say they will continue to fight against the fine imposed on them earlier this year for allegedly colluding to exclude Roche's Avastin from the ophthalmology market in favor of Novartis's much more expensive Lucentis, despite losing their first challenge in the Italian courts1,2.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.